Drug resistance in multiple myeloma: addressing the issue
Brian Van Ness
Reducing the risk of secondary malignancies in lymphoma
How durable are the responses of CLL patients to therapy?
Recent developments in the mutational landscape and molecular basis of AML
Factors to consider in frontline and relapsed CLL before treatment